Comparative effectiveness of inebilizumab versus conventional immunotherapies in AQP4-IgG-positive NMOSD: a prospective cohort study with time-varying treatment effects

医学 内科学 前瞻性队列研究 危险系数 硫唑嘌呤 队列 比例危险模型 不利影响 队列研究 美罗华 临床试验 逆概率加权 入射(几何) 耐受性 视神经脊髓炎 肿瘤科 人口
作者
Wenjuan Huang,Xintong Zhang,Zhouzhou Wang,Jingzi ZhangBao,Lei Zhou,Xiang Li,Hongmei Tan,Qiang Dong,Chao Quan
出处
期刊:Journal of Neurology, Neurosurgery, and Psychiatry [BMJ]
卷期号:: jnnp-2026
标识
DOI:10.1136/jnnp-2026-339197
摘要

BACKGROUND: To compare relapse and disability outcomes of inebilizumab, azathioprine (AZA), mycophenolate mofetil (MMF) and rituximab (RTX) in maintenance-therapy-naive patients with aquaporin-4 IgG-positive neuromyelitis optica spectrum disorder. METHODS: We prospectively enrolled 566 patients (inebilizumab n=72, AZA n=196, MMF n=170, RTX n=128). Primary effectiveness analyses were conducted in the per-protocol cohort (n=528), with supportive analyses in the full cohort. Both used inverse probability of treatment weighting to estimate the average treatment effect on the treated, with inebilizumab as reference. Primary outcomes were annualised relapse rate (ARR) and time to first relapse; disability progression was secondary. Adverse events (AEs) were assessed in the full cohort. RESULTS: In the per-protocol cohort, median age was 37 years, 477 (90.3%) were female and median follow-up was 21.5 months. Compared with inebilizumab, ARR was higher with AZA (incidence rate ratio (IRR) 4.78), MMF (IRR 4.33) and RTX (IRR 2.26; all p<0.05). Average relapse hazards were higher with AZA (HR 3.77; p=0.006) and MMF (HR 4.05; p=0.003), but not significantly different with RTX (hazard ratio (HR) 2.08; p=0.178). Time-varying analysis suggested a higher relapse hazard with RTX only during the first 6 months. Supportive analyses in the full cohort yielded consistent results. AZA and MMF were associated with greater disability progression than inebilizumab, whereas RTX was not. Severe AEs did not differ across groups. CONCLUSIONS: Inebilizumab was associated with better relapse and disability outcomes than AZA or MMF. Compared with RTX, inebilizumab was associated with lower ARR, whereas no significant differences were detected in time to first relapse or disability progression.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
烟花的应助被科研通管家采纳,获得10
刚刚
无花果的应助被科研通管家采纳,获得10
刚刚
Xide完成签到,获得积分10
刚刚
moon完成签到,获得积分10
刚刚
桐桐的应助被科研通管家采纳,获得10
1秒前
田様的应助被科研通管家采纳,获得10
1秒前
小蘑菇的应助被科研通管家采纳,获得10
1秒前
achilles发布了新的文献求助10
1秒前
酷波er的应助被科研通管家采纳,获得10
1秒前
1秒前
1秒前
大模型的应助被科研通管家采纳,获得10
1秒前
1秒前
Owen的应助被你很棒采纳,获得30
1秒前
2秒前
2秒前
3秒前
风吹麦浪的应助被名古邬采纳,获得20
3秒前
初景发布了新的文献求助10
4秒前
今后的应助被斯多姆采纳,获得10
4秒前
4秒前
Eternity完成签到,获得积分10
4秒前
天天快乐的应助被Jase采纳,获得10
5秒前
津津完成签到,获得积分10
5秒前
yosh发布了新的文献求助10
5秒前
十一完成签到 ,获得积分10
5秒前
jie发布了新的文献求助10
6秒前
莓莓发布了新的文献求助10
6秒前
冰棍发布了新的文献求助10
6秒前
苁蓉远志完成签到 ,获得积分10
6秒前
molihuakai的应助被白春蕾采纳,获得10
7秒前
7秒前
MIN完成签到,获得积分10
8秒前
狮子发布了新的文献求助10
8秒前
NOIR4LU完成签到 ,获得积分10
8秒前
一谷完成签到 ,获得积分10
8秒前
白XX发布了新的文献求助10
9秒前
xyt完成签到 ,获得积分10
9秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527